ArticleESMO gastrointestinal oncology2025
Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy.
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Prognostic Stratification After Perioperative FLOT in Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicenter Real-World Study.Journal of clinical medicine · 2026Article
- Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment. Materials and methods: We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan-Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria. Results: A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, Conclusions: Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.